The Claim
In obese, nondiabetic women, 30% are high responders to a 16-week exenatide treatment regimen, achieving at least a 5% reduction in body weight with an average weight loss of 7.96%, while 31% are nonresponders who experience weight gain with an average increase of 1.93%, indicating substantial individual variability in treatment response.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
Some women who are obese but don’t have diabetes lose a good amount of weight on a drug called exenatide for 16 weeks, but almost as many actually gain weight — showing it works very differently from person to person.
See the scientific wording
In obese, nondiabetic women, 30% are high responders to 16-week exenatide treatment, losing at least 5% of body weight (average 7.96% loss), while 31% are nonresponders who gain weight (average 1.93% gain), demonstrating substantial individual variability in response.
What the research says
1 studyThe study looked at how obese women who don’t have diabetes responded to a 16-week exenatide treatment, and found that some lost a lot of weight, some lost a little, and some even gained weight—just like the claim says.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.